- Home
- MTNB vs XAIR Comparison
MTNB vs XAIR Comparison
Compare MTNB & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | XAIR |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.3M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MTNB | XAIR |
|---|---|---|
| Price | $0.23 | $6.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 5.7M | 39.3K |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $119,750.00 | ★ $7,679,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $0.23 | $0.33 |
| 52 Week High | $2.24 | $8.19 |
Technical Indicators
Market Signals| Indicator | MTNB | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 62.82 |
| Support Level | $0.23 | $0.64 |
| Resistance Level | $0.65 | $7.96 |
| Average True Range (ATR) | 0.04 | 0.73 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 8.42 | 47.44 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About XAIR Beyond Air Inc.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.